PDCD1 and acute lymphoblastic leukemia: Another ongoing phase 1–2 study (NCT03160079) has also shown blinatumomab in combination with a PD-1 inhibitor, pembrolizumab, to be effective and relatively safe in patients with r/r B-ALL.